Cocrystal Pharma, Inc. · NASDAQ:COCP
Cocrystal Pharma — World Vaccine Congress West Coast 2023
18 slides from Cocrystal Pharma's conference presentation, Nov 29, 2023
Slide 1: Taking a New Route: Development of novel inhaled and oral Polymerase PB2 Inhibitor, CC-42344
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the expected future characteristics and progress in our clinical programs, including our ongoing Phase 2a study
Slide 3: CC-42344: Potential Influenza Therapeutic and Prophylactic Treatments
CC-42344: Potential Influenza Therapeutic and Prophylactic Treatments Influenza PB2 CC-42344 _ van Cocrystal structure of CC-42344 (1.47 A) Properties of CC-42344 ie) Oo ie) Favorable safety profile Potent, broad-spectrum activity against pandemic and seasonal strains High barrier to resistance Supe
Slide 4: Trimeric RNA Polymerase Complex
Trimeric RNA Polymerase Complex PBI Nucleus ys | \ Viral RNA PLIXF- IP I~. Host pre-mRNA ( Chimeric RNA Kram > ; aie “Cap snatching” Ons AAA ya as Endonucleolytic Cleavage Boivin S et al. J. Biol. Chem. 2010;285:28411-28417 Cytoplasm elF4E Translation Ribosome complex
Slide 5: CC-42344 Binds to Highly Conserved Active Site of Influenza A PB2-Protein
CC-42344 Binds to Highly Conserved Active Site of Influenza A PB2-Protein Cocrystal proprietary drug discovery platform technology C®CRYSTAL RA
Slide 6: CC-42344 Shows Broad-spectrum Antiviral Activity Against Pandemic and Seasonal Influenza A Strains
CC-42344 Shows Broad-spectrum Antiviral Activity Against Pandemic and Seasonal Influenza A Strains Influenza Serotype St H1N1 A/PR/8/34 1 Pandemic H1N1 California/04/2009 0.5 H1N1 A1/Denver/1/57 3 H1N1 A/Fort Monmouth/1/47 2 H1N1 A/NY/18/09 5 H3N2 A/AICHI/2/68 0.2 Highly pathogenic Avian H5N1 Duck/M
Slide 7: CC-42344 Exhibits Superior Antiviral Activity Compared to Oseltamivir
CC-42344 Exhibits Superior Antiviral Activity Compared to Oseltamivir CC-42344 exhibits superior antiviral activity at higher MOls (multiplicity of infection) CC-42344 Vs Oseltamivir 1005 > ot MOI 0.005 = MOI 0.05 ‘5 754 MOI 0.5 MOI 0.005 ‘s ‘a MOIS > ry = 50 a (=) i o a 255 MOI 0.05 x MOI 0.5 04 Mo
Slide 8: Cocrystal Structure-Based Drug Discovery Platform Technology
Cocrystal Structure-Based Drug Discovery Platform Technology Delivers Multiple Broad-Spectrum Antiviral Leads, Influenza and Others Cocrystal technology uniquely offers: Systematic analysis of drug binding pockets for broad-spectrum antivirals Rapid crystal structure determination and computational
Slide 9: Oral CC-42344: Phase 1 Data Demonstrates Favorable Safety Profile, Advancing to Phase 2a
Oral CC-42344: Phase 1 Data Demonstrates Favorable Safety Profile, Advancing to Phase 2a Phase 1 site: Linear Clinical Research — Harry Perkins Research Institute, Perth, Australia Participants: = Single-center, randomized, double-blind, placebo-controlled = Single-ascending dose, multiple-ascending
Slide 10: Development of Novel Inhaled PB2 Inhibitor, CC-42344
Development of Novel Inhaled PB2 Inhibitor, CC-42344 Advantages of inhalation antiviral therapy = Directly targets infected respiratory epithelial cells = Achieves higher accumulation of drug in the pulmonary system = Produces rapid clinical response = Reduces potential systemic side effects X 10 C@
Slide 11: Evaluating Toxicity in In Vitro Human Upper Airway Epithelium
Evaluating Toxicity in In Vitro Human Upper Airway Epithelium (A) Trans-epithelial electrical resistance determination (B) Lactate dehydrogenase oH Formazan GED "( oy. wow 2 4-7 wae Cite beating Greiquiency = fac Vans “measurement ~ pis we 4 8Y Me Mean CBF : 11.367 He Median CBF: 11.719 Hz Standard
Slide 12: CC-42344 Showed Favorable Safety Profile in Human Upper Airway Epithelium
CC-42344 Showed Favorable Safety Profile in Human Upper Airway Epithelium (A) Trans-epithelial electrical resistance determination (B) Lactate dehydrogenase CC-42344 207 me alow en es Mm 26 hours Wm 48 hours Ml 72 hours ; = z q pe hours 6 eo $ CC-42344 ry 0 0 7 Untreated Vehicle O.1HM 1uM 10M. Trito
Slide 13: CC-42344 Antiviral Activity in Human Upper Airway Epithelium
it Antiviral Activity in In iN‘ Human Upper Airway Epithelium / HANA # No CC-42344 No F; . treatment : f sad Uninfected human upper airway epithelia by scanning electron microscopy Mas aay With CC-42344
Slide 14: Oral Inhalation Formulation Development Completed
Oral Inhalation Formulation Development Completed (A) Prototype dry powder manufacturing (B) Aerodynamic particle size distribution MMAD = 2.84 + 0.09 um CC-42344 dry powder Z z, i 1 | Be CC-42344 in capsules on — oo ta “se re ° CC-42344 in Inhalers 14 C®CRYSTAL
Slide 15: Inhaled CC-42344: Potential Prophylactic and Therapeutic Treatment
Inhaled CC-42344: Potential Prophylactic and Therapeutic Treatment Inhaled CC-42344 achieves high exposure in lung = 1000 ECs >20,000-fold at 24 hr a 100 EC,, >5,000-fold at 96 hr 5 10 = g 1 Plasma 5 0.1 ECsq >20-fold at 24 hr o 5 00tg we ECgo, 2:nM O 0.001 ====== Bp rena sssesseees aneenee ECs, 1 n
Slide 16: CC-42344 In an Inhaler Device Showed Excellent Dissolution and Absorption Rates
CC-42344 In an Inhaler Device Showed Excellent Dissolution and Absorption Rates Using Precise Inhale Aerosol Generator and Dissolv/t® Precise Inhale aerosol generator (Inhalation Sciences) = CC-42344 CC-42344 zy -® Dissolved (Plasma) 8 -® Non-dissolved (Lung) 12} | i : 0 T T T 1 i) 60 120 180 240 Ti
Slide 17: CC-42344: Potential Influenza Therapeutic and Prophylactic Treatment Summary
CC-42344: Potential Influenza Therapeutic and Prophylactic Treatment SUMMARY = Favorable safety profile = Potent, broad-spectrum activity against pandemic and seasonal strains = High barrier to resistance = Superior pulmonary pharmacology: high exposure and long half-life, ECs, >5,000-fold at 96 hr
Slide 18: Slide 18
Cocrystal Pharma — World Vaccine Congress West Coast 2023 on 6ix